Quick Answer
Immunome Inc. reported Diluted EPS of $2.43 per share (loss) for fiscal year 2025.
Immunome Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.43 | +51.4% |
| 2024 | -$5.00 | +7.1% |
| 2023 | -$5.38 | -74.1% |
| 2022 | -$3.09 | -44.4% |
| 2021 | -$2.14 | +59.3% |
| 2020 | -$5.26 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.65 | +16.7% | -30.0% |
| June 30, 2025 | -$0.50 | +16.7% | +3.8% |
| March 31, 2025 | -$0.52 | +79.3% | +33.3% |
| September 30, 2024 | -$0.78 | -116.7% | -30.0% |
| June 30, 2024 | -$0.60 | -30.4% | +76.1% |
| March 31, 2024 | -$2.51 | -617.1% | -597.2% |
| September 30, 2023 | -$0.36 | +52.0% | +21.7% |
| June 30, 2023 | -$0.46 | +37.8% | -31.4% |
- Immunome Inc. showed an increase of +51.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Immunome Inc.’s diluted eps has grown by 53.8% (from $5.26 per share (loss) to $2.43 per share (loss)).
- The most recent figure is from Immunome Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: